undamentalytics Newsletter
Sign in

Zentalis Pharmaceuticals, Inc. (ZNTL) stock

Add to watchlist

Add holding +

NASDAQ: ZNTL Nasdaq Biotechnology Next results ~November 10, 2026

Zentalis Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 4 selling2 purchases and 10 sales by directors and officers, last 12 monthsInsider trades
  • Funds63 adding, 51 cuttingOf 28 active managers that changed their stake, 13 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 23% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Zentalis Pharmaceuticals, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 129% and a beta of 2.0 against the S&P 500.
  • Short interest rising. Shares sold short rose 25% in a month to 7.1% of tradable shares.

Latest results

Earnings per share
-$0.59 against an average estimate of -$0.48: missed by 22.9%
Share reaction
-14.7% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 10, 2026; average EPS estimate -$0.52

Zentalis Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.1%
  • 1 week-10.4%
  • 1 month-29.6%
  • This year+37.0%
  • 1 year+23.3%
  • 5 years-97.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Zentalis Pharmaceuticals, Inc. valuation models and calculator

No model value for Zentalis Pharmaceuticals, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.52 (range −$0.63 to −$0.42) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.98 −10% — 0%
Next −$1.74 +12% $10m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +18.5% on 90 days ago. In the last 30 days, 1 analyst raised Zentalis Pharmaceuticals, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Zentalis Pharmaceuticals, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.67 Current fiscal year, 60 days ago: −$2.11 Current fiscal year, 30 days ago: −$2.11 Current fiscal year, 7 days ago: −$2.02 Current fiscal year, Now: −$1.98 −$1.98 Next fiscal year, 90 days ago: −$1.53 Next fiscal year, 60 days ago: −$1.81 Next fiscal year, 30 days ago: −$1.81 Next fiscal year, 7 days ago: −$1.77 Next fiscal year, Now: −$1.74 −$1.74

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.67−$1.53
60 days ago −$2.11−$1.81
30 days ago −$2.11−$1.81
7 days ago −$2.02−$1.77
Now −$1.98−$1.74

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.48 −$0.59 −22.9%
Dec 2025 −$0.61 −$0.49 +19.9%
Sept 2025 −$0.48 −$0.37 +22.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

11 analysts, Oct 2026
Buy873%
Hold327%
Sell00%

Monthly trend

  1. Oct 20268311
  2. Sep 20266511
  3. Aug 20265510
  4. Jul 20265510

Counts of recommendations published by analysts covering Zentalis Pharmaceuticals, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.1%
of tradable shares
Days to cover
4.4
at average volume
Short interest, 1 month
+25%
to October 15, 2026
Held by institutions
51%
of shares
Held by insiders
21.9%
of shares
Employees
106
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ZNTL+62%−76%−25%−80%−55%+37%
Industry peers (median)−36%−56%−17%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ZNTL67%25%42%42%25%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ZNTL−32%−79%−67%−84%−68%−72%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since April 3, 2020: 99% from November 3, 2021 to April 8, 2025. Getting back needed a 8053% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.28 – $6.61
From 52-week high
−72.0%
vs 50-day average
−36.4%
vs 200-day average
−46.3%
Volatility (1 year)
129%
Beta vs S&P 500
2.01

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±10.8%
After a week
5 up, 7 down
typical move ±10.3%
After a month
5 up, 7 down
typical move ±18.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −14.7% +0.5% −16.2% −19.4%
May 12, 2026 +3.4% +0.4% −14.5% −15.0%
March 26, 2026 −17.6% −3.5% +3.1% +66.7%
November 10, 2025 +9.4% +1.8% +3.1% +10.9%
August 6, 2025 +2.8% +0.7% +5.7% +24.1%
May 14, 2025 +4.1% +0.6% 0.0% +10.7%
March 26, 2025 −4.3% −1.5% −27.5% −23.5%
August 9, 2024 −8.8% +0.5% −5.4% −1.2%
May 7, 2024 +6.1% +0.1% −0.4% −5.5%
February 27, 2024 +10.0% +0.1% +1.3% +7.9%
November 6, 2023 −43.0% +0.5% −42.6% −33.1%
August 9, 2023 +5.3% −0.6% +3.6% −0.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$229M
Institutions reporting
114
Shares held vs prior quarter
▲ 8.8%
Positions opened / closed
35 / 19

Top buyers and sellers, Q2 2026: 63 institutions bought and 51 sold ; the biggest buyer was Blackrock, Inc (+2.5M shares) and the biggest seller D. E. Shaw & Co., Inc (−938K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
5Am Venture Management, LLC $19.1M 3.9M 8.4% 0.0%
Blackrock, Inc. $18.2M 3.8M 8.0% ▲ 195.6%
Squadron Capital Management LLC $17.9M 3.7M 7.8% ▲ 1.9%
Two Sigma Investments, LP $14.7M 3.0M 6.4% ▲ 2.3%
Vanguard Capital Management LLC $13.8M 2.8M 6.0% ▲ 22.7%
Acadian Asset Management LLC $13M 2.7M 5.7% ▼ 5.8%
Citadel Advisors LLC $11.1M 2.3M 4.9% ▲ 32.7%
Renaissance Technologies LLC $7.8M 1.6M 3.4% ▼ 17.0%
Opaleye Management Inc. $6.9M 1.4M 3.0% 0.0%
Orbimed Advisors LLC $6.7M 1.4M 2.9% New
Decheng Capital LLC $6.4M 1.3M 2.8% 0.0%
Geode Capital Management, LLC $6.2M 1.3M 2.7% ▲ 106.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Zentalis Pharmaceuticals, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $22.9M 2 trades by 1 insider, last 12 months Insider sales History → $10.1M 10 trades by 4 insiders · 1% under pre-set plans
Net ▲ $12.8M net buying
Insider Date Trade Shares Price Value
Walters William Thurman 10% owner August 14, 2026 Buy 4,335,000 $3.50 $15.2M
Vultaggio Vincent PAO and PFO February 10, 2026 Sell pre-set plan 6,894 $2.42 $16,683
Eastland Julia Marie CEO & President February 9, 2026 Sell 889 $2.39 $2,125
Vultaggio Vincent PAO and PFO February 9, 2026 Sell pre-set plan 3,379 $2.39 $8,076
Bruns Ingmar Chief Medical Officer February 9, 2026 Sell 335 $2.39 $801
Eastland Julia Marie CEO & President February 6, 2026 Sell 7,866 $2.43 $19,114
Vultaggio Vincent PAO and PFO February 6, 2026 Sell pre-set plan 29,951 $2.43 $72,781
Bruns Ingmar Chief Medical Officer February 6, 2026 Sell 2,962 $2.43 $7,198
Vultaggio Vincent PAO and PFO February 3, 2026 Sell pre-set plan 556 $2.52 $1,401
Vultaggio Vincent PAO and PFO February 2, 2026 Sell pre-set plan 2,540 $2.55 $6,477
Walters William Thurman 10% owner December 31, 2025 Buy 6,459,973 $1.20 $7.8M
Goel David E. 10% owner December 15, 2025 Sell 7,500,000 $1.33 $10M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 12, 2026
  • March 26, 2026
  • November 10, 2025
  • August 6, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Zentalis Pharmaceuticals, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Zentalis Pharmaceuticals, Inc. in brief

What does Zentalis Pharmaceuticals, Inc. do?
Zentalis Pharmaceuticals, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Zentalis Pharmaceuticals, Inc.'s stock ticker?
Zentalis Pharmaceuticals, Inc. trades under the ticker ZNTL on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Zentalis Pharmaceuticals, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are 5Am Venture Management, LLC, Blackrock, Inc. and Squadron Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Zentalis Pharmaceuticals, Inc. stock?
Over the last 12 months, Zentalis Pharmaceuticals, Inc.'s directors and officers reported 2 open-market purchases and 10 sales on Form 4. The insider trading page charts every trade.
When is Zentalis Pharmaceuticals, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Zentalis Pharmaceuticals, Inc. announces its own schedule.